SANTA BARBARA, CA / ACCESSWIRE / October 9, 2023 / Santa Barbara Nutrients, Inc. is pleased to announce that our…
REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of…
PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW),…
TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of…
The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire…
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB),…
KENTFIELD, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- ZKR Orthopedics, Inc., a clinical stage medical device company, today announced that…
Topline results expected in 2H 2024CARMEL, Ind., Oct. 09, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical…
NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing…
First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical Study in Chronic Inducible Urticaria…